Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection.

Main goal in drug discovery is the identification of drug-like compounds capable to modulate specific biological targets. Thus, the prediction of reliable binding poses of candidate ligands, through molecular docking simulations, represents a key step to be pursued in structure-based drug design (SBDD). Since the increasing number of resolved three-dimensional ligand-protein structures, together with the expansion of computational power and software development, the comprehensive and systematic use of experimental data can be proficiently employed to validate the docking performance. This allows to select and refine the protocol to adopt when predicting the binding pose of trial compounds in a target. Given the availability of multiple docking software, a comparative docking assessment in an early research stage represents a must-use step to minimize fails in molecular modeling. This chapter describes how to perform a docking assessment, using freely available tools, in a semiautomated fashion.

[1]  Tudor I. Oprea,et al.  Theoretical and Practical Aspects of Three‐Dimensional Quantitative Structure‐Activity Relationships , 2007 .

[2]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[3]  G. Marshall,et al.  Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy. , 2017, Bioorganic & medicinal chemistry.

[4]  Alexander D. MacKerell,et al.  Computer-Aided Drug Design Methods. , 2017, Methods in molecular biology.

[5]  P. Lam,et al.  1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2006, Bioorganic & medicinal chemistry letters.

[6]  Garland R. Marshall,et al.  An Automated Strategy for Binding-Pose Selection and Docking Assessment in Structure-Based Drug Design , 2016, J. Chem. Inf. Model..

[7]  Yat T Tang,et al.  Virtual screening for lead discovery. , 2011, Methods in molecular biology.

[8]  Ruben Abagyan,et al.  Comparative study of several algorithms for flexible ligand docking , 2003, J. Comput. Aided Mol. Des..

[9]  F. Diederich,et al.  Molecular recognition in chemical and biological systems. , 2015, Angewandte Chemie.

[10]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[11]  Shaomeng Wang,et al.  An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes , 2004, J. Chem. Inf. Model..

[12]  Martin Stahl,et al.  Modifications of the scoring function in FlexX for virtual screening applications , 2000 .

[13]  Stefan Senger,et al.  Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[14]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[15]  François Diederich,et al.  Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. , 2005, Angewandte Chemie.

[16]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[17]  Sung-Hou Kim,et al.  Structural basis for chemical inhibition of human blood coagulation factor Xa. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Rino Ragno,et al.  3-D QSAutogrid/R: An Alternative Procedure To Build 3-D QSAR Models. Methodologies and Applications , 2012, J. Chem. Inf. Model..

[19]  William J. Allen,et al.  DOCK 6: Impact of new features and current docking performance , 2015, J. Comput. Chem..

[20]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[21]  A. Spada,et al.  Crystal structures of human factor Xa complexed with potent inhibitors. , 2000, Journal of medicinal chemistry.

[22]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[23]  G. Marshall,et al.  Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. , 2017, European journal of medicinal chemistry.